Targeting leukemic stem cells: the path towards the cure of poor-prognosis leukemia

Back to search results
PROJECT DESCRIPTION

Leukemic stem cells (LSCs) are the major cause of treatment failure in acute myeloid leukemia (AML), a highly lethal blood cancer with a 5-year survival rate of only 27%. We have previously uncovered several key oncogenic pathways involved in the regulation of survival and self-renewal of LSCs (e.g., Science 2010; Blood 2014; Leukemia 2016; Leukemia 2019). This project will develop new strategies to identify pathway inhibitors in order to eradicate drug-resistant LSCs. The efficacy of new inhibitors will be tested in highly translational patient-derived xenograft models. Ablating LSCs is the important part of a successful anti-cancer therapy for aggressive AML.

IDEAL CANDIDATE

An ideal HDR candidate to undertake this project will have knowledge and prior experience in cancer research, cellular biology or molecular biology. The candidate is able to demonstrate strong research and analytical skills.
Supervisory team
Jenny
Wang

Medicine
Women's & Children's Health
Nicola
Smith

Medicine
St Vincent's Clinical School
Tracey
O'Brien

Medicine
Women's & Children's Health
jenny.wang@unsw.edu.au